DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity.
Kohei Takano, Mayuko Yukiura, Kazuki Takahashi...
https://pubmed.ncbi.nlm.nih.gov/40635151/Actively Recruiting
Led by Daiichi Sankyo · Updated on 2026-10-15
590
Participants Needed
61
Research Sites
13 weeks
Total Duration
Researchers are evaluating DS-3939a, an antibody drug conjugate ADC, for safety, tolerability, and effectiveness in adults with advanced solid tumors, including locally advanced, metastatic, or unresectable cancers. This first-in-human phase 12 clinical trial is divided into two parts dose escalation and dose expansion, focusing on participants with measurable disease and good performance status. Participants will receive DS-3939a as an intravenous infusion every 3 weeks on Day 1 of each 21-day cycle. The study includes a dose escalation part where dosing starts at 1 mgkg and a dose expansion part with multiple cohorts targeting various advanced solid tumors. Treatment continues with monitoring for dose-limiting toxicities and response rates over approximately 31 months. During the study, participants will undergo assessments including tumor biopsies, echocardiograms, and laboratory tests to monitor organ function and immune response. Researchers will track adverse events, tumor response, and pharmacokinetics through scheduled visits and sample collections. The study may last up to nearly 5 years, including treatment and follow-up periods, to evaluate long-term safety and efficacy outcomes.
CONDITIONS
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
(
(US Sites) Daiichi Sankyo Contact for Clinical Trial Information
(
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Daiichi Sankyo
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | DS‑3939a (TA‑MUC1 ADC) |
|---|---|
| What it is | DS‑3939a is an investigational antibody‑drug conjugate targeting tumor‑associated mucin‑1 (TA‑MUC1), combining a humanized anti‑TA‑MUC1 antibody with a topoisomerase I inhibitor payload (DXd) administered intravenously every 21 days. |
| Role in the trial | It serves as the sole investigational treatment evaluated in two sequential parts: dose‑escalation (Part 1) followed by dose‑expansion (Part 2) in patients with advanced solid tumors. |
| Primary use investigated | Evaluated for safety, tolerability, dose‑limiting toxicities, and objective tumor response rate in advanced solid tumors. |
| How it is given | Administered as an intravenous infusion on Day 1 of each 21‑day cycle. |
| Evidence status | Early clinical data showed a safety and tolerability profile consistent with other ADCs, including dose‑limiting toxicities evaluated in dose‑escalation cohorts. |
| Important limitations | As a first‑in‑human single‑arm study, there is no direct comparison arm; efficacy and safety benchmarks rely on historical or external data. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 31 months
Participants receive DS-3939a by intravenous infusion every 3 weeks on Day 1 of each 21-day cycle. Dose escalation starts at 1 mg/kg, followed by dose expansion in multiple cohorts targeting various advanced solid tumors.
Visits every 3 weeks for infusion and monitoring
Duration - Up to approximately 16 months after treatment
Participants are monitored for long-term safety, adverse events, and tumor response. Assessments include laboratory tests, biopsies, and imaging to evaluate treatment effects.
Periodic visits for safety and response evaluations
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kohei Takano, Mayuko Yukiura, Kazuki Takahashi...
https://pubmed.ncbi.nlm.nih.gov/40635151/Daiichi Sankyo
Lead Sponsor